Revised SPCs: Cosentyx (secukinumab) 150 mg solution for injection in pre-filled pen and syringe

SPCs revised to warn that cases of new or exacerbations of inflammatory bowel disease (IBD) have been reported with secukinumab, therefore it not recommended in patients with IBD and should be discontinued in those who develops signs and symptoms or a flare up of IBD.


electronic Medicines compendium